$421 Million is the total value of Boxer Capital, LLC's 27 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 43.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVXS | Sell | AVEXIS INC | $65,728,000 | -16.0% | 800,000 | -22.2% | 15.63% | -8.5% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $46,815,000 | -26.5% | 500,000 | -50.0% | 11.13% | -20.0% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $46,280,000 | +2.8% | 1,000,000 | -21.6% | 11.01% | +11.9% |
| BGNE | Sell | BEIGENE LTDsponsored adr | $27,000,000 | -13.2% | 600,000 | -29.4% | 6.42% | -5.6% |
| Sell | MEDICINES COMPANYcall | $20,168,000 | -39.7% | 530,600 | -22.4% | 4.80% | -34.3% | |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $12,668,000 | -58.9% | 250,000 | -67.5% | 3.01% | -55.2% |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $7,387,000 | -49.6% | 525,000 | -40.2% | 1.76% | -45.1% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $2,448,000 | -26.8% | 425,000 | -45.3% | 0.58% | -20.3% |
| ONTX | Sell | ONCONOVA THERAPEUTICS INC | $654,000 | -32.0% | 302,886 | -4.3% | 0.16% | -25.7% |
| NVET | Exit | NEXVET BIOPHARMA PUB LTD CO | $0 | – | -154,840 | -100.0% | -0.13% | – |
| ARDMQ | Exit | ARADIGM CORP | $0 | – | -576,208 | -100.0% | -0.20% | – |
| AKTX | Exit | AKARI THERAPEUTICS PLCsponsored adr | $0 | – | -95,011 | -100.0% | -0.23% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -50,000 | -100.0% | -0.30% | – |
| ALDX | Exit | ALDEYRA THERAPEUTICS INC | $0 | – | -291,230 | -100.0% | -0.32% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -75,000 | -100.0% | -1.99% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -250,000 | -100.0% | -2.80% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Aviva Holdings Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
| F-star Therapeutics, Inc. | February 14, 2022 | ? | ? |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-14 |
| SC 13D/A | 2024-05-14 |
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.